Frederick H. Rein

Frederick Rein is Of Counsel in Goodwin’s Intellectual Property Litigation practice.

He is a globally-minded, tech-focused attorney who is licensed to practice law in New York and California, registered to practice at the United States Patent and Trademark Office, and admitted before various federal courts including the United States District Court for the Central District of California where he previously clerked.

Fred served two terms as chair of the American Intellectual Property Law Association’s IP Practice in Israel Committee.

Before joining Goodwin in 2001, Fred was a partner at another law firm.

Fred is accredited by the International Association of Privacy Professionals as a Certified Information Privacy Manager (CIPM), Certified Information Privacy Professional – Europe and the United States (CIPP/E + CIPP/US), and Certified Information Privacy Technologist (CIPT).

Some of Fred’s publications include the following:

• “Ninth Circuit Limits CFAA To Digital “Breaking And Entering,” Finds LinkedIn Likely Has No CFAA Claim Against Web Scraper,” Goodwin Alert, April 2022
• “Amgen v. Sanofi: The fall of the newly characterized antigen test (if it ever truly, jurisprudentially existed in the first place),” Journal of Generic Medicines, May 2019
• “Extraterritoriality and infringement of blockchain claims,” World Intellectual Property Review, September 2018
• “Time To Remove Patent Barriers To US Drug Manufacturing,” Law360, August 2018
• “Amgen v. Sanofi: Can an injunction contrary to the public health interest ever properly be granted?” Journal of Generic Medicines, June 2018
• “Awkward Positions: Second Circuit Confronts Dueling Claims for Deference,” New York Law Journal, May 2018
• “Stumbling Blocks: Proving Infringement of Blockchain Claims, Issues of Decentralisation and Extraterritoriality,” Intellectual Property Magazine, March 2018
• “Incentivizing Brand Pharma Cos. To Manufacture In The US,” Law360, June 2017
• “Making America Manufacture Drugs Again,” Law360, March 2017
• “Galderma Labs. v. Tolmar Inc.: Determining the contours of when a claimed concentration is obvious in view of a prior art range of concentrations,” Journal of Generic Medicines, December 2014
• “Pozen Inc. v. Par Pharmaceutical, Inc.: “Fuzzy” limitations and the doctrine of equivalents,” Journal of Generic Medicines, December 2013
• “The America Invents Act: Post Grant And Inter Partes Review In The Era Of Biosimilar Biological Products,” Update Magazine, March/April 2012
• “AstraZeneca v. Apotex: Section viii statement or approved label – a Hobson’s choice?,” Journal of Generic Medicines, October 2011
• “Healthcare Reform Creates Pathway for Biosimilar Biologics,” IP Frontline, April 2010
• “A Discussion of Generic Drug Approval and Patent Systems in the United States and Canada,” Canadian Intellectual Property Review, June 2009
• “Abbott v Torpharm: The Contours of Contempt,” Journal of Generic Medicines, July 2008
• “Abraxis v Mayne: What You Say Can, and will, be Used against You,” Journal of Generic Medicines, April 2007
• “Purdue v Endo: ‘It Ain't Over Till It's over’,” Journal of Generic Medicines, April 2006

SPEAKING ENGAGEMENTS

Fred has moderated or spoken at various events, including those organized by the American Israel Public Affairs Committee, the Israeli chapter of AIPPI (Association Internationale pour la Protection de la Propriété Intellectuelle), the Food and Drug Law Institute, the Hebrew University Faculty of Law, the Intellectual Property Institute of Canada, the International Generic and Biosimilar Medicines Association, and the New York City Bar Association.